ES2053552T3 - Moleculas con lugares de combinacion de anticuerpo que muestran propiedades cataliticas. - Google Patents

Moleculas con lugares de combinacion de anticuerpo que muestran propiedades cataliticas.

Info

Publication number
ES2053552T3
ES2053552T3 ES87308175T ES87308175T ES2053552T3 ES 2053552 T3 ES2053552 T3 ES 2053552T3 ES 87308175 T ES87308175 T ES 87308175T ES 87308175 T ES87308175 T ES 87308175T ES 2053552 T3 ES2053552 T3 ES 2053552T3
Authority
ES
Spain
Prior art keywords
molecules
catalytic properties
antibody combination
showing catalytic
league
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87308175T
Other languages
English (en)
Spanish (es)
Inventor
Alfonso Tramontano
Kim D Janda
Richard A Lerner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Clinic and Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Clinic and Research Foundation filed Critical Scripps Clinic and Research Foundation
Application granted granted Critical
Publication of ES2053552T3 publication Critical patent/ES2053552T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/32—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4056—Esters of arylalkanephosphonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/42—Halides thereof
    • C07F9/425—Acid or estermonohalides thereof, e.g. RP(=X)(YR)(Hal) (X, Y = O, S; R = H, or hydrocarbon group)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5537—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom the heteroring containing the structure -C(=O)-N-C(=O)- (both carbon atoms belong to the heteroring)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
ES87308175T 1986-09-17 1987-09-16 Moleculas con lugares de combinacion de anticuerpo que muestran propiedades cataliticas. Expired - Lifetime ES2053552T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90831386A 1986-09-17 1986-09-17
US07/086,896 US5030717A (en) 1986-09-17 1987-08-18 Antibodies which catalyze hydrolysis of ester bonds

Publications (1)

Publication Number Publication Date
ES2053552T3 true ES2053552T3 (es) 1994-08-01

Family

ID=26775276

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87308175T Expired - Lifetime ES2053552T3 (es) 1986-09-17 1987-09-16 Moleculas con lugares de combinacion de anticuerpo que muestran propiedades cataliticas.

Country Status (13)

Country Link
US (1) US5030717A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0260939B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2556869B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU620019B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1312835C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3785633T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK175518B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2053552T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI94026C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3007997T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE61322B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO171223C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT85750B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229272A (en) * 1989-04-25 1993-07-20 Igen, Inc. Catalytic antibody components
US4963355A (en) * 1986-06-23 1990-10-16 Igen, Inc. Production of antibody catalysts
DE3889041T2 (de) * 1987-09-02 1994-10-27 Igen Inc Herstellung von Immunonähe-Katalysatoren.
ZA893284B (en) * 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
US6702705B1 (en) * 1988-05-04 2004-03-09 Igen International, Inc. Prodrugs activated by targeted catalytic proteins
US5215889A (en) * 1988-11-18 1993-06-01 The Regents Of The University Of California Catalytic and reactive polypeptides and methods for their preparation and use
US5236825A (en) * 1989-01-17 1993-08-17 Scripps Clinic And Research Foundation Polyvalent metal ion-containing antibody combining site catalysts
US5429936A (en) * 1989-04-21 1995-07-04 The Regents Of The University Of California Antibody-mediated juxtaposition of reactive moieties
US6048717A (en) * 1989-04-25 2000-04-11 Igen International, Inc. Inhibitors of catalytic antibodies
US5236836A (en) * 1989-04-25 1993-08-17 Igen, Inc. Autoantibodies which enhance the rate of a chemical reaction
US5599538A (en) * 1989-04-25 1997-02-04 Igen, Inc. Autoantibodies which enhance the rate of a chemical reaction
US5658753A (en) * 1989-04-25 1997-08-19 Paul; Sudhir Catalytic antibody components
US5194585A (en) * 1989-04-25 1993-03-16 Igen, Inc. Inhibitors of catalytic antibodies
DK547589D0 (da) * 1989-11-02 1989-11-02 Novo Nordisk As Fremgangsmaade til fremstilling af organiske forbindelser
US5444155A (en) * 1991-09-10 1995-08-22 The Scripps Research Institute Molecules with antibody combining sites that induce asymmetry
US5250426A (en) * 1991-10-22 1993-10-05 The Scripps Research Institute Molecules with antibody combining sites that induce asymmetry
US5463028A (en) * 1992-04-03 1995-10-31 The Trustees Of Columbia University In The City Of New York Reagents for generating a polyclonal hydrolytic antibody response against cocaine and the monoclonal hydrolytic antibodies against cocaine derived through these reagents
JP2721296B2 (ja) * 1993-09-08 1998-03-04 株式会社蛋白工学研究所 糖エステル誘導体を位置選択的に加水分解する触媒抗体
US5571681A (en) * 1994-03-10 1996-11-05 The Scripps Research Institute Chemical event selection by suicide substrate conjugates
GB9510830D0 (en) * 1995-05-27 1995-07-19 Zeneca Ltd Proteins
EP0854934A4 (en) * 1995-08-18 2000-09-06 Donald W Landry DETECTION OF ORGANIC COMPOUNDS BY REGULATION OF ANTIBODY CATALYZED REACTIONS
US5948658A (en) 1996-06-25 1999-09-07 The Trustees Of Columbia University In The City Of New York Anti-cocaine catalytic antibody
WO2001032908A1 (fr) * 1999-10-29 2001-05-10 Wakamoto Pharmaceutical Co., Ltd. Anticorps monoclonal, hybridome, immunoessai et necessaire a diagnostic
KR102283200B1 (ko) 2012-03-14 2021-07-29 리제너론 파마슈티칼스 인코포레이티드 다중특이성 항원-결합 분자 및 그것의 용도
NZ737726A (en) 2015-07-06 2023-03-31 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
IL271193B2 (en) 2017-06-07 2025-01-01 Regeneron Pharma Preparations and methods for internalizing enzymes
JP2021512899A (ja) 2018-02-07 2021-05-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 治療用タンパク質送達のための方法および組成物
EP3788075A1 (en) 2018-04-30 2021-03-10 Regeneron Pharmaceuticals, Inc. Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof
MA52626A (fr) 2018-05-17 2021-03-24 Regeneron Pharma Anticorps anti-cd63, conjugués et leurs utilisations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888281A (en) * 1983-11-29 1989-12-19 Igen, Inc. Method of catalyzing chemical reactions
US4659567A (en) * 1984-09-07 1987-04-21 Scripps Clinic & Research Foundation Molecules with antibody combining sites that bind to hydrolytic transition states
US4963355A (en) * 1986-06-23 1990-10-16 Igen, Inc. Production of antibody catalysts
US4792446A (en) * 1986-06-23 1988-12-20 Igen, Inc. Production of antibody catalysts

Also Published As

Publication number Publication date
FI94026B (fi) 1995-03-31
NO171223B (no) 1992-11-02
FI94026C (fi) 1995-07-10
DE3785633T2 (de) 1993-08-12
IE872512L (en) 1988-03-17
FI874047L (fi) 1988-03-18
PT85750A (en) 1987-10-01
NO171223C (no) 1993-02-10
GR3007997T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-08-31
PT85750B (pt) 1990-08-31
JPS63159325A (ja) 1988-07-02
AU7843487A (en) 1988-03-24
US5030717A (en) 1991-07-09
CA1312835C (en) 1993-01-19
EP0260939B1 (en) 1993-04-28
DK486087D0 (da) 1987-09-16
EP0260939A2 (en) 1988-03-23
FI874047A0 (fi) 1987-09-16
DK175518B1 (da) 2004-11-22
DK486087A (da) 1988-03-18
DE3785633D1 (de) 1993-06-03
JP2556869B2 (ja) 1996-11-27
EP0260939A3 (en) 1990-04-18
NO873884L (no) 1988-03-18
AU620019B2 (en) 1992-02-13
NO873884D0 (no) 1987-09-16
IE61322B1 (en) 1994-11-02

Similar Documents

Publication Publication Date Title
ES2053552T3 (es) Moleculas con lugares de combinacion de anticuerpo que muestran propiedades cataliticas.
HN1997000110A (es) Derivados del acido arilsulfoonilamino hidroxamico
ES2119241T3 (es) Procedimiento para la obtencion de insulina con puentes de cistina unidos correctamente.
BR8804193A (pt) Pedra para lavagem(a gas)e processo para a sua fabricacao
MX172953B (es) Derivados de 2-aminopirimidina-4-carboxamida, su preparacion y su aplicacion en terapeutica
ES2120959T3 (es) Moleculas con sitios de combinacion de anticuerpos que catalizan reacciones de hidrolisis.
ATE134874T1 (de) Synoviale phospholipasen
MX166109B (es) Preparacion de piperacinonas n-sustituidas
FI880151A0 (fi) -glutamyylitranspeptidaasin käyttö glutaryyli-7-amino- tai -ketoadipinyylikefalosporaanihapon entsymaattiseen hydrolysointiin
NO913474D0 (no) Enzymatisk fremgangsmaate for omdanning av preproinsulin til insulin.
PT89282A (pt) Processo para a hidrolise enzimatica de monoaminocompostos de alfa-aminoadipinilo
DE3787882D1 (de) Enzym vermittelnde Kupplungsreaktionen.
DK0865435T3 (da) Fremgangsmåde til fremstilling af 3-amino-1,2,4-benzotriazin-dioxid
ES2083427T3 (es) Procedimiento para fabricar 2-oxindol-1-carboxamidas.
ATE40993T1 (de) Herstellung von n-substituierten azetidin-3carbons|urederivaten.
PT78738A (pt) Processo para a preparacao de fluoreto de isobutirilo
FI874612A0 (fi) Foerfarande foer framstaellning av beta-hydroxismoersyra och dess salter medelst hydrolysering av oligomerer av beta-hydroxismoersyra vid basiska betingelser.
ES514117A0 (es) "procedimiento para la preparacion de l-prolina".
IT8023834A0 (it) Fibra acrilica adatta come precursore di fibre di carbonio o grafite.
ES2017459B3 (es) Procedimiento de obtencion de alfa-halogeno-alquil arilcetonas opticamente activas.
DK162766C (da) Fremgangsmaade til fremstilling af thiotetronsyre
PT94670A (pt) Processo para a preparacao do antibiotico antitumor bu-3285t
ES8102267A1 (es) Perfeccionamientos en puentes de fijacion para adosar a los tramos de canal de un transportador rascador de cadena para explotaciones subterraneas
KR900004712A (ko) 하이드로스민의 제조방법
KR880701434A (ko) 다수의 압축 드라이버를 혼에 연결하기 위한 어답터

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 260939

Country of ref document: ES